Company Description

Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina.

Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer’s disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies.

The company was incorporated in 2007 and is headquartered in Purchase, New York.

Cognition Therapeutics, Inc.

Country	United States
Founded	2007
IPO Date	Oct 8, 2021
Industry	Biotechnology
Sector	Healthcare
Employees	28
CEO	Lisa Ricciardi

Contact Details

Address: 2500 Westchester Ave. Purchase, New York 10577 United States
Phone	412 481 2210
Website	cogrx.com

Stock Details

Ticker Symbol	CGTX
Exchange	NASDAQ
Fiscal Year	January - December
Reporting Currency	USD
IPO Price	$12.00
CIK Code	0001455365
CUSIP Number	19243B102
ISIN Number	US19243B1026
SIC Code	2836

Key Executives

Name	Position
Lisa Ricciardi	Chief Executive Officer, President and Director
John Brendan Doyle	Chief Financial Officer
Dr. Anthony O. Caggiano M.D., Ph.D.	Chief Medical Officer and Head of Research & Development
Dr. Steven A. Weissman Ph.D.	Vice President and Head of CMC
Anita Cornet	Head of Quality
Bobby Horn	Corporate Controller

Latest SEC Filings

Date	Type	Title
Nov 13, 2024	10-Q	Quarterly Report
Nov 13, 2024	8-K	Current Report
Oct 1, 2024	8-K	Current Report
Sep 13, 2024	8-K	Current Report
Aug 28, 2024	8-K	Current Report
Aug 8, 2024	10-Q	Quarterly Report
Aug 8, 2024	8-K	Current Report
Jul 29, 2024	8-K	Current Report
Jun 7, 2024	8-K	Current Report
May 7, 2024	10-Q	Quarterly Report

View All SEC Filings